Rua Bioscience Limited
RUA.NZ
New Zealand Exchange0.03
NZD
- -
- -
Rua Bioscience Limited
RUA.NZ
(New Zealand Exchange)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rua Bioscience Limited (NZX: RUA) is a New Zealand-based Māori-owned biotechnology company specializing in the research, development, cultivation, extraction, manufacturing, and global distribution of cannabinoid-derived medicinal cannabis products; it offers GMP-certified dried flower, oils, and extracts including the proprietary Rua Rau Hiwa brand featuring unique New Zealand legacy genetics with THC and CBD for conditions such as sleep disorders, anxiety, chronic pain, and chemotherapy-induced nausea; the company also advances plant breeding, seed production, genetic discovery programs, and emerging psilocybin initiatives for mental health and addiction treatment. Founded in 2017 and headquartered at 704 Te Araroa Road, Ruatoria in the Tairāwhiti region of New Zealand's East Cape, Rua Bioscience pioneered the local medicinal cannabis sector as the first entity licensed for cannabis cultivation research and maintains a subsidiary, Rua Bioscience Australia Pty Ltd, to support operations; it targets pharmaceutical markets serving patients through clinics, distributors, and pharmacies with a focus on social impact, community well-being, and intergenerational value in Te Tairāwhiti. The company supplies products to key markets including Germany, Australia, New Zealand, the United Kingdom, and Czechia via international supply agreements and partnerships; it emphasizes superior genetics from its Ruatorea centre of excellence for export-oriented production at global scale. Recent developments include a November 2025 rights offer capital raise targeting working capital for sales growth in five core markets and crop cultivation; securing exclusive New Zealand distribution rights for a medical device in November 2025; product launch into Czechia marking a major EU expansion milestone in September 2025; over 500% year-on-year revenue growth reported in FY25 with record quarterly sales in November 2025 driven by strong European demand and Australian clinic partnerships; approval of a debt facility in May 2025 to accelerate sales; a positive legal resolution with Cann in June 2025; ongoing psilocybin clinical trial updates; and strategic efforts to outsource manufacturing following an uncompleted asset sale while pursuing new purchasers.